Condition: Rheumatoid Arthritis · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy adult participants.
This description comes directly from the study's public registry record.
Yiting Chi, Master · +86 13482779422 · chiyiting@genscigroup.com
Always discuss trial participation with your own doctor first.
| Huashan Hospital Affiliated to Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07040930